Hypomethylation of VTRNA2-1 promoter predicts adverse outcomes in peripheral artery disease
VTRNA2-1 hypomethylation is associated with increased risk of limb-related complications in PAD patients, especially among those without ESRD. These findings suggest that VTRNA2-1 methylation status may serve as a promising biomarker for refining risk stratification in PAD. Further validation in external cohorts and mechanistic studies are warranted.
Authors
- Jih-Kai Yeh
- Hsieh IC
- Chao‐Yung Wang (ORCID: https://orcid.org/0000-0003-1546-7298)
- Chun-Chi Chen (ORCID: https://orcid.org/0009-0002-7856-2276)
- Wen Fan
- Chin-Yuan Chia
- Yi-Chun Huang
- Ming-Lung Tsai
- Chi-Neu Tsai
Institutions
- Chang Gung University of Science and Technology (TW)
- National Health Research Institutes (TW)
- Chang Gung University (TW)
- National Tsing Hua University (TW)
- Chang Gung Memorial Hospital (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
- Taipei City Hospital (TW)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2026-02-27
- DOI
- https://doi.org/10.1186/s13148-026-02087-z
- Primary Topic
- Peripheral Artery Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00